TY - JOUR
T1 - Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples
AU - Riester, Markus
AU - Wei, Wei
AU - Waldron, Levi
AU - Culhane, Aedin C.
AU - Trippa, Lorenzo
AU - Oliva, Esther
AU - Kim, Sung Hoon
AU - Michor, Franziska
AU - Huttenhower, Curtis
AU - Parmigiani, Giovanni
AU - Birrer, Michael J.
PY - 2014/5/14
Y1 - 2014/5/14
N2 - Background Ovarian cancer causes more than 15000 deaths per year in the United States. The survival of patients is quite heterogeneous, and accurate prognostic tools would help with the clinical management of these patients. Methods We developed and validated two gene expression signatures, the first for predicting survival in advanced-stage, serous ovarian cancer and the second for predicting debulking status. We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested models by a leave-one-dataset-out procedure, and validated models in additional independent datasets. Selected genes from the debulking signature were validated by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in two further independent cohorts of 179 and 78 patients, respectively. All statistical tests were two-sided. Results The survival signature stratified patients into high-and low-risk groups (hazard ratio = 2.19; 95% confidence interval [CI] = 1.84 to 2.61) statistically significantly better than the TCGA signature (P =. 04). POSTN, CXCL14, FAP, NUAK1, PTCH1, and TGFBR2 were validated by qRT-PCR (P
AB - Background Ovarian cancer causes more than 15000 deaths per year in the United States. The survival of patients is quite heterogeneous, and accurate prognostic tools would help with the clinical management of these patients. Methods We developed and validated two gene expression signatures, the first for predicting survival in advanced-stage, serous ovarian cancer and the second for predicting debulking status. We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested models by a leave-one-dataset-out procedure, and validated models in additional independent datasets. Selected genes from the debulking signature were validated by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in two further independent cohorts of 179 and 78 patients, respectively. All statistical tests were two-sided. Results The survival signature stratified patients into high-and low-risk groups (hazard ratio = 2.19; 95% confidence interval [CI] = 1.84 to 2.61) statistically significantly better than the TCGA signature (P =. 04). POSTN, CXCL14, FAP, NUAK1, PTCH1, and TGFBR2 were validated by qRT-PCR (P
UR - http://www.scopus.com/inward/record.url?scp=84902460514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902460514&partnerID=8YFLogxK
U2 - 10.1093/jnci/dju048
DO - 10.1093/jnci/dju048
M3 - Article
C2 - 24700803
AN - SCOPUS:84902460514
SN - 0027-8874
VL - 106
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 5
M1 - dju048
ER -